Janney Montgomery Scott LLC Sells 6,603 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Janney Montgomery Scott LLC trimmed its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 9.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 66,126 shares of the biotechnology company’s stock after selling 6,603 shares during the period. Janney Montgomery Scott LLC’s holdings in ADMA Biologics were worth $1,134,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of ADMA Biologics by 13.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock worth $13,171,000 after acquiring an additional 80,400 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after purchasing an additional 92,281 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in shares of ADMA Biologics in the 3rd quarter valued at $61,858,000. EWG Elevate Inc. acquired a new position in shares of ADMA Biologics during the 4th quarter worth $480,000. Finally, Citigroup Inc. lifted its position in shares of ADMA Biologics by 251.7% during the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock worth $7,741,000 after buying an additional 277,138 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $16.90 on Wednesday. The business’s 50-day moving average price is $17.90 and its 200-day moving average price is $17.66. ADMA Biologics, Inc. has a 12 month low of $5.02 and a 12 month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $3.99 billion, a price-to-earnings ratio of 60.36 and a beta of 0.75.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the previous year, the firm posted $0.01 EPS. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

Insider Buying and Selling

In other news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 3.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have commented on ADMA. Raymond James boosted their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.